Navigation Links
HealthSouth Finalizes Sale of Corporate Campus to Daniel Corporation
Date:3/31/2008

BIRMINGHAM, Ala., March 31 /PRNewswire-FirstCall/ -- HealthSouth Corporation (NYSE: HLS) today announced it has finalized the sale of its corporate campus, located in Birmingham, Ala., to Daniel Corporation, a Birmingham-based, full-service real estate organization, for $43.5 million in cash and a 40% residual interest in the "Digital Hospital." In addition, HealthSouth has entered into a long-term lease arrangement with Daniel Corporation to maintain its corporate headquarters on the property. On January 23, 2008, HealthSouth announced that it had reached a definitive agreement for this sale.

The sale includes the 103-acre corporate campus and all related buildings including a 200,000 square-foot corporate headquarters building, the Cahaba Grand Conference Center, and an incomplete 13-story building formerly called the "Digital Hospital."

The sale of the corporate campus is part of the strategic repositioning of HealthSouth, first announced in August 2006, as a post-acute healthcare provider, focusing on inpatient rehabilitative and other complementary services. Proceeds from this transaction will be used to pay down a portion of the company's long-term debt.

"We are very pleased to finalize this transaction with Daniel Corporation," said HealthSouth President and CEO Jay Grinney. "This is another step in our plan to reposition HealthSouth as the preeminent provider of inpatient rehabilitative services in the U.S. The sale of this property will help us reduce corporate operating expenses, while the proceeds from the sale will be used to pay down additional debt."

Additional details of the agreement were not disclosed.

About HealthSouth

HealthSouth is the nation's largest provider of inpatient reha
'/>"/>

SOURCE HealthSouth Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. HealthSouth to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference and the 2008 Credit Suisse Global Leveraged Finance Conference
2. HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007
3. HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock
4. HealthSouth Issues Statement on Medicare Bill and 75% Rule
5. HealthSouth Announces Final Agreement on Previously Disclosed Settlement with Federal Government
6. HealthSouth and Physicians Pay $14.9 Million to Settle Health Care Fraud Claims
7. HealthSouth Announces Date of Third Quarter Earnings Conference Call
8. HealthSouth Corporation Appoints New Member to Board of Directors
9. HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock
10. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
11. Independence Blue Cross Finalizes New Multi-Year Agreements with Mercy Health System and St. Mary Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Heska Announces Extension of Credit Agreement With Wells Fargo 2Heska Announces Extension of Credit Agreement With Wells Fargo 3Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lee's Pharmaceuticals 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 3Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 1Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 2Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 3Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 4Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 5Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 6Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 7Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 8Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 9Golden Meditech Announces HK 24217 Million Private Equity Financing for Hospital Subsidiary 14309 1Golden Meditech Announces HK 24217 Million Private Equity Financing for Hospital Subsidiary 14309 2Method to Identify Female Athletes at a High Risk for Knee Injury Discovered 58628 1Method to Identify Female Athletes at a High Risk for Knee Injury Discovered 58628 2